secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001104659-24-044496
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics: MT-601 shows durable CR in lymphoma patient 9 months post-CAR T failure; 3/3 objective responses
--------------------------------------------------------------------------------

- First APOLLO participant with DLBCL who relapsed after CAR T remains in complete response 9 months after MT-601 treatment.
- Second participant with transformed follicular NHL achieved CR at 8 weeks and remains in CR at 3 months.
- Third participant with DLBCL (CAR T-ineligible) achieved partial response at 8 weeks with lesion shrinkage.
- All three patients tolerated treatment well; no cytokine release syndrome or neurotoxicity reported.
- Data presented at 11th Global Summit on Hematologic Malignancies on April 6, 2024 by City of Hope PI Dr. Shouse.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924044496/0001104659-24-044496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924044496/tm2411143d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-044496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer